The authors reported that breast cancer cells with KDM5A gene amplification and hence, with up-regulated KDM5A mRNA and protein levels, were found to be more tolerant to the EGF receptor TKI erlotinib when compared to cells without the same amplification[62]. This evidence concerns the gene KDM5A and breast carcinoma.